Intra-Cellular raises $60m, goes public in reverse merger
This article was originally published in Scrip
Executive Summary
Intra-Cellular Therapies raised $60m in a private sale of common stock and became a public company through a reverse merger into an inactive publicly-traded shell corporation to finance the development of drugs to treat central nervous system disorders.